Vireo Growth (VREOF) Net Income towards Common Stockholders Growth (1y) (2021 - 2026)
Vireo Growth (VREOF) Net Income towards Common Stockholders Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.07 Bn | 39.42 Bn | 2.15 Bn | -304.98% |
| 3 | Zoetis | 31.53 Bn | 29.85 Bn | 1.05 Bn | -5.04% |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | -17.29% |
| 5 | United Therapeutics | 22.13 Bn | 19.47 Bn | 683.80 Mn | 7.59% |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -2,482.61% |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | 34.33% |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 390.91% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | Vireo Growth | 491.44 Mn | 349.14 Mn | 95.30 Mn | 48.35% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -562.98% |
| Dec 31, 2025 | -903.06% |
| Sep 30, 2025 | -37.16% |
| Jun 30, 2025 | -9.54% |
| Mar 31, 2025 | 31.38% |
| Dec 31, 2024 | 17.77% |
| Sep 30, 2024 | 176.72% |
| Jun 30, 2024 | 154.92% |
| Mar 31, 2024 | 143.68% |
| Dec 31, 2023 | 138.44% |
| Sep 30, 2023 | 40.16% |
| Jun 30, 2023 | -21.07% |
| Mar 31, 2023 | 52.10% |
| Dec 31, 2022 | 34.06% |
| Sep 30, 2022 | -39.96% |
| Jun 30, 2022 | 12.65% |
| Mar 31, 2022 | -148.61% |
| Dec 31, 2021 | -350.44% |
| Sep 30, 2021 | -230.74% |
| Jun 30, 2021 | 56.58% |